CDMO News
Boehringer Ingelheim Expands Contract Manufacturing in China with Regulatory Reform
Boehringer Ingelheim BioXcellence™ has secured approval to participate in China’s segmented manufacturing reform, a regulatory initiative led by the National Medical Products Administration (NMPA). This programme aims to enhance efficiency and flexibility in the production of biological products. With this qualification,
10 March 2025
Stay ahead of trends and best practices
